Defeating cancer: the 150 most important questions in cancer research and clinical oncology.

Chin J Cancer

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China.

Published: December 2016

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192589PMC
http://dx.doi.org/10.1186/s40880-016-0165-4DOI Listing

Publication Analysis

Top Keywords

defeating cancer
4
cancer 150
4
150 questions
4
questions cancer
4
cancer clinical
4
clinical oncology
4
defeating
1
0
1
questions
1
cancer
1

Similar Publications

Mesenchymal stem/stromal cells: dedicator to maintain tumor homeostasis.

Hum Cell

November 2024

School of Medicine, Jiangsu University, 301 Xuefu Road, Zhenjiang, 212013, Jiangsu, People's Republic of China.

Article Synopsis
  • * MSCs support tumor growth by connecting with various cell types in the TME and possess properties that help maintain tumor progression.
  • * The article explores how MSCs contribute to tumor homeostasis and highlights the importance of understanding TME components to improve cancer therapy strategies.
View Article and Find Full Text PDF

Nanotechnology-Assisted CAR-T-Cell Therapy for Tumor Treatment.

Wiley Interdiscip Rev Nanomed Nanobiotechnol

October 2024

Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.

The adoptive transfer of T cells redirected by chimeric antigen receptors (CARs) has made a dramatic breakthrough in defeating hematological malignancies. However, in solid tumor treatment, CAR-T-cell therapy has attained limited therapeutic benefits due to insufficient infiltration and expansion, rapidly diminishing function following adoptive transfer, and severe life-threatening toxicities. To address these challenges, advancements in nanotechnology have utilized innovative approaches to devise stronger CAR-T cells with reduced toxicity and enhanced anti-tumor activity.

View Article and Find Full Text PDF

HMGA1 stimulates cancer stem-like features and sensitivity to monensin in gastric cancer.

Exp Cell Res

October 2024

i3S-Institute for Research and Innovation in Health, University of Porto, 4200-135, Porto, Portugal; IPATIMUP-Institute of Molecular Pathology and Immunology, University of Porto, 4200-465, Porto, Portugal. Electronic address:

Gastric cancer represents a serious health problem worldwide, with insufficient molecular biomarkers and therapeutic options. Consequently, several efforts have been directed towards finding specific disease markers in order to develop new therapies capable of defeating gastric cancer. Attention has been pointed to cancer stem cells (CSCs) as they are primarily responsible for tumor initiation and recurrence, making them essential therapeutic targets.

View Article and Find Full Text PDF

The complexity and compensatory evolution of tumors weaken the effectiveness of single antitumor therapies. Therefore, multimodal combination therapies hold great promise in defeating tumors. Herein, we constructed a multi-level regulatory co-delivery system based on chemotherapy, phototherapy, and immunotherapy.

View Article and Find Full Text PDF

Introduction: Patients with clinically node-negative breast cancer have a negative sentinel lymph node status (pN0) in approximately 75% of cases and the necessity of routine surgical nodal staging by sentinel lymph node biopsy (SLNB) has been questioned. Previous prediction models for pN0 have included postoperative variables, thus defeating their purpose to spare patients non-beneficial axillary surgery. We aimed to develop a preoperative prediction model for pN0 and to evaluate the contribution of mammographic breast density and mammogram features derived by artificial intelligence for de-escalation of SLNB.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!